Edgewise Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer | Option Exercise | 100,000 | $0.18 | $18,000 | Nov 12, 2025 |
| Fox Jonathan C | — | Purchase | 10,700 | $18.64 | $199,448 | Nov 11, 2025 |
| Fox Jonathan C | — | Award / Grant | 728 | — | — | Oct 1, 2025 |
| Russell Alan J | Chief Scientific Officer | Option Exercise | 100,000 | $0.18 | $18,000 | Aug 26, 2025 |
| MOORE JOHN R | General Counsel | Option Exercise | 5,781 | — | — | Aug 12, 2025 |
| Derakhshan Behrad | Chief Business Officer | Option Exercise | 5,781 | — | — | Aug 12, 2025 |
| Carruthers R Michael | Chief Financial Officer | Sale | 1,428 | $13.39 | $19,121 | Aug 12, 2025 |
| Russell Alan J | Chief Scientific Officer | Option Exercise | 5,781 | — | — | Aug 12, 2025 |
| KOCH KEVIN | President and CEO | Option Exercise | 17,968 | — | — | Aug 12, 2025 |
| Donovan Joanne M. | CMO | Option Exercise | 5,781 | — | — | Aug 12, 2025 |
| Fox Jonathan C | — | Award / Grant | 858 | — | — | Jul 1, 2025 |
| Russell Alan J | Chief Scientific Officer | Option Exercise | 5,209 | — | — | May 2, 2025 |
| MOORE JOHN R | General Counsel | Option Exercise | 5,209 | — | — | May 2, 2025 |
| KOCH KEVIN | President and CEO | Sale | 4,276 | $16.45 | $70,340 | May 1, 2025 |
| Donovan Joanne M. | CMO | Sale | 5,187 | $16.45 | $85,326 | May 1, 2025 |
| Derakhshan Behrad | Chief Business Officer | Sale | 1,691 | $16.45 | $27,817 | May 1, 2025 |
| Carruthers R Michael | Chief Financial Officer | Sale | 1,314 | $16.45 | $21,615 | May 1, 2025 |
| Thompson Peter A. | — | Purchase | 124,193 | $20.13 | $2,500,005 | Apr 3, 2025 |
| OrbiMed Genesis GP LLC | — | Purchase | 372,578 | $20.13 | $7,499,995 | Apr 3, 2025 |
| Fox Jonathan C | — | Award / Grant | 559 | — | — | Apr 1, 2025 |
| Russell Alan J | Chief Scientific Officer | Sale | 200 | $30.02 | $6,004 | Mar 7, 2025 |
| KOCH KEVIN | President and CEO | Option Exercise | 100 | $0.18 | $18 | Mar 7, 2025 |
| Russell Alan J | Chief Scientific Officer | Option Exercise | 1,200 | $0.18 | $216 | Feb 5, 2025 |
| KOCH KEVIN | President and CEO | Sale | 8,636 | $30.03 | $259,339 | Feb 5, 2025 |
| Derakhshan Behrad | Chief Business Officer | Sale | 10,000 | $30.03 | $300,300 | Feb 5, 2025 |
| Donovan Joanne M. | CMO | Sale | 25,000 | $27.63 | $690,750 | Jan 28, 2025 |
| Russell Alan J | Chief Scientific Officer | Sale | 100,000 | $27.37 | $2,737,000 | Dec 30, 2024 |
| Semigran Marc | Chief Development Officer | Sale | 1,729 | $30.08 | $52,008 | Dec 24, 2024 |
| Carruthers R Michael | Chief Financial Officer | Option Exercise | 70,000 | $0.71 | $49,700 | Oct 11, 2024 |
| MOORE JOHN R | General Counsel | Option Exercise | 50,000 | $0.71 | $35,500 | Sep 23, 2024 |
| Russell Alan J | Chief Scientific Officer | Sale | 815 | $29.51 | $24,051 | Sep 20, 2024 |
| Donovan Joanne M. | CMO | Sale | 7,162 | $28.29 | $202,613 | Sep 20, 2024 |
| Derakhshan Behrad | Chief Business Officer | Sale | 42,068 | $29.03 | $1,221,234 | Sep 20, 2024 |
| Carruthers R Michael | Chief Financial Officer | Sale | 50,000 | $28.55 | $1,427,500 | Sep 20, 2024 |
| Derakhshan Behrad | Chief Business Officer | Option Exercise | 5,208 | — | — | May 2, 2024 |
| Russell Alan J | Chief Scientific Officer | Option Exercise | 5,208 | — | — | May 2, 2024 |
| Donovan Joanne M. | CMO | Option Exercise | 10,417 | — | — | May 2, 2024 |
| MOORE JOHN R | General Counsel | Sale | 1,956 | $18.91 | $36,988 | May 1, 2024 |
| Carruthers R Michael | Chief Financial Officer | Sale | 2,157 | $18.91 | $40,789 | May 1, 2024 |
| KOCH KEVIN | President and CEO | Sale | 3,152 | $18.91 | $59,604 | May 1, 2024 |
| Derakhshan Behrad | Chief Business Officer | Option Exercise | 600 | $1.93 | $1,158 | Feb 9, 2024 |
| MOORE JOHN R | General Counsel | Sale | 17,993 | $20.00 | $359,860 | Feb 7, 2024 |
| Carruthers R Michael | Chief Financial Officer | Sale | 90,000 | $15.78 | $1,420,200 | Jan 23, 2024 |
| Thompson Peter A. | — | Purchase | 454,545 | $11.00 | $4,999,995 | Jan 23, 2024 |
| OrbiMed Capital GP VI LLC | — | Purchase | 454,545 | $11.00 | $4,999,995 | Jan 23, 2024 |
| MOORE JOHN R | General Counsel | Sale | 8,497 | $10.50 | $89,219 | Dec 27, 2023 |
| Fox Jonathan C | — | Purchase | 10,857 | $9.30 | $100,970 | Dec 26, 2023 |
| Russell Alan J | Chief Scientific Officer | Sale | 172,585 | $9.33 | $1,610,218 | Dec 26, 2023 |
| Carruthers R Michael | Chief Financial Officer | Option Exercise | 10,000 | $0.71 | $7,100 | Jun 22, 2023 |
| Derakhshan Behrad | Chief Business Officer | Option Exercise | 5,208 | — | — | May 2, 2023 |